Sarwar Zahid, MD
Retina Specialist · Jackson Heights, NYNPI 1972845287
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by AbbVie at 27.9% of the total. Reporting peaked in 2024 at $12,608 and has fallen 54.9% since, to $5,686 in 2025.
Across 115 payments — averaging $249.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Regeneron$7K
- Heidelberg Engineering, Inc.$5K
- Alcon$3K
- Alimera Sciences, Inc.$2K
- Eyepoint US, Inc.$2K
- plus $3K from 18 others
What the payments were for
- Consulting fees$15,88355%
- Speaking & faculty fees$4,49716%
- Travel & lodging$2,4208%
- Food & beverage$5,66120%
- Education$1280%
- Gifts$190%
- Entertainment$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $7,991 |
| Regeneron | 11 | $6,703 |
| Heidelberg Engineering, Inc. | 6 | $4,973 |
| Alcon | 15 | $2,847 |
| Alimera Sciences, Inc. | 11 | $1,866 |
| Eyepoint US, Inc. | 3 | $1,721 |
| Regeneron Healthcare Solutions, Inc. | 7 | $603 |
| Apellis Pharmaceuticals, Inc. | 3 | $224 |
| Biotissue Holdings Inc. | 2 | $224 |
| Novartis | 2 | $201 |
| Bausch & Lomb Americas Inc. | 2 | $193 |
| Genentech USA, Inc. | 2 | $156 |
| Astellas Pharma US Inc | 1 | $147 |
| Spark Therapeutics, Inc. | 1 | $125 |
| Mallinckrodt Hospital Products Inc. | 1 | $100 |
| Amgen(2 entities) | 5 | $96 |
| Harrow Eye, LLC | 1 | $94 |
| Oyster Point Pharma, Inc. | 3 | $83 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Samsara Vision | 1 | $68 |
| Glaukos Corporation | 1 | $60 |
| ANI Pharmaceuticals, Inc. | 2 | $46 |
| Optos, Inc. | 2 | $26 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$6,466
- EYLEA HD$6,403
- Spectralis$4,941
- EYP-1901$1,615
- Iluvien$1,515
- YUTIQ$1,515
- NGENUITY$1,347
- Unity$907
- EYLEA$339
- Constellation$281
- Izervay$147
- Lucentis$125
- DURYSTA$125
- LUXTURNA$125
- LUMIGAN$122
- Syfovre$119
- Prokera$114
- AmnioGraft$114
- DEXYCU$106
- enVista MX60 IOL$104
How this compares
$28,635 in reported general payments places this provider in the 85th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 41 | $99,563 |
| OzurdexDexamethasone | 40 | $68,438 |
| RestasisCyclosporine | 75 | $58,059 |
| Eylea HdAflibercept | 13 | $53,642 |
| XiidraLifitegrast | 33 | $24,402 |
| Prednisolone Acetate | 84 | $3,760 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 77 | $973 |
| Latanoprost | 91 | $844 |
| Brimonidine Tartrate | 22 | $559 |
| Timolol Maleate | 36 | $471 |
| Ofloxacin | 19 | $366 |
| Ketorolac Tromethamine | 13 | $346 |
| Dorzolamide Hcl | 19 | $250 |
| Azelastine Hcl | 15 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd | $603 | $153,20554 claims |
| AbbVieOzurdex, Restasis | $7,991 | $126,497115 claims |
| Bausch & Lomb Americas Inc.Xiidra | $193 | $24,40233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 99 retina specialist providers in New York.
Other retina specialist in Jackson Heights
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
- Matthew WitmerRochester$62K
- Avnish DeobhaktaBrooklyn$46K
- Edward HallRochester$38K
- Philip NilesWilliamsville$30K
- Mark BreazzanoLiverpool$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.